Division of Infectious Diseases, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Department of Neonatology, Kanagawa Children's Medical Center, Kanagawa, Japan.
Hum Vaccin Immunother. 2021 May 4;17(5):1313-1316. doi: 10.1080/21645515.2020.1826799. Epub 2020 Oct 29.
The exact impact of the decline in childhood vaccination coverage during COVID-19 outbreak has not been estimated for any vaccine-preventable diseases. Our objective was to evaluate the impact of decreased mumps vaccination due to COVID-19 on the disease burden of mumps in Japan. Using a previously validated dynamic transmission model of mumps infection in Japan, the incidence rate of mumps over the next 30 y since July 2020 was estimated. The estimated average incidences were 269.1, 302.0, and 455.4/100,000 person-years in rapid recovery, slow recovery, and permanent decline scenarios. Compared with the rapid recovery scenario, the incremental number of mumps cases, total costs, and QALYs loss over the next 30 y were 6.53 million cases, 2.63 billion USD, and 49,246 for the permanent decline scenario, respectively. In conclusion, the persistent decline of mumps vaccination rate as an impact of COVID-19 causes a significant incremental disease burden of mumps, which is consistent irrespective of the possible decline of transmission rate of mumps infection, unless the rapid recovery of coverage rate is achieved. The immediate measures to advocate the vaccination program is essential to mitigate the incremental disease burden in the COVID-19 period.
由于 COVID-19 爆发,儿童疫苗接种率下降,这对任何可预防疾病的具体影响都尚未评估。我们的目的是评估因 COVID-19 导致腮腺炎疫苗接种减少对日本腮腺炎疾病负担的影响。使用日本腮腺炎感染的先前验证的动态传播模型,估计了自 2020 年 7 月以来未来 30 年的腮腺炎发病率。在快速恢复、缓慢恢复和永久性下降情景下,预计腮腺炎的平均发病率分别为 269.1、302.0 和 455.4/100,000 人年。与快速恢复情景相比,永久性下降情景下未来 30 年的腮腺炎病例增量、总成本和 QALY 损失分别为 653 万例、26.3 亿美元和 49246。总之,COVID-19 导致腮腺炎疫苗接种率持续下降,这将导致腮腺炎疾病负担显著增加,除非接种率迅速恢复,否则这种情况与腮腺炎感染传播率可能下降无关。在 COVID-19 期间,倡导疫苗接种计划是减轻新增疾病负担的重要措施。